149818-98-4

Basic information

• Product Name: METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE
• Synonyms: METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE;methyl (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylphenyl)propanoate
• CAS NO: 149818-98-4
• Molecular Formula: C₂₁H₂₅NO₄
• Molecular Weight: 355.43
• Mol File: 149818-98-4.mol

Chemical Properties

• Boiling Point: 508.646°C at 760 mmHg
• Flash Point: 261.42°C
• Appearance: /
• Density: 1.113g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.538
• PKA: 10.95±0.46(Predicted)
• CAS DataBase Reference: METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE(149818-98-4)
• EPA Substance Registry System: METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE(149818-98-4)

Safety Data

• Hazardous Substances Data: 149818-98-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE is used as a building block for the synthesis of peptides and proteins, contributing to the development of new pharmaceuticals. Its unique structure allows for the creation of complex peptide sequences that can be tailored for specific therapeutic applications.
Used in Protein Structure and Function Studies:
In the field of biochemistry and molecular biology, METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE is used as a research tool for studying protein structure and function. The biphenyl group's steric hindrance can influence the conformation and interactions of proteins, providing insights into their mechanisms of action and potential modifications for enhanced performance.
Used in Organic Chemistry:
METHYL-N-TERT-BUTYLOXYCARBONYL-AMINO-4,4'-BIPHENYL-R-ALANINE is used as a key intermediate in organic synthesis, particularly for the preparation of complex organic molecules with specific properties. Its versatility in chemical reactions makes it a valuable component in the synthesis of a wide range of compounds, including those with potential applications in materials science, pharmaceuticals, and other industries.

InChI:InChI=1/C21H25NO4/c1-21(2,3)26-20(24)22-18(19(23)25-4)14-15-10-12-17(13-11-15)16-8-6-5-7-9-16/h5-13,18H,14H2,1-4H3,(H,22,24)/t18-/m1/s1

Upstream product

• 176794-86-8 (Z)-methyl 3-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acrylate 
• 98-80-6 phenylboronic acid 
• 123795-38-0 methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-(4-chlorophenyl)propanoate 
• 100-63-0 phenylhydrazine 
• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 
• 459133-43-8 (R)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride 
• 100-58-3 phenylmagnesium bromide 
• 1431556-38-5 C₁₆H₂₃NO₇S 
• 100-59-4 phenylmagnesium chloride 
• 91853-46-2 3-([1,1'-biphenyl]-4-yl)-2-oxopropanoic acid 
• 1188995-14-3 (Z)-4-([1,10-biphenyl]-4-ylmethylene)-2-methyloxazol-5(4H)-one 
• 1057002-37-5 4-[1-biphenyl-4-yl-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 753421-85-1 ethyl (γS)-γ-amino-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-58-0 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanal 
• 149709-63-7 α-ethyl (γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-63-7 α-ethyl (αS,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-62-6 α-ethyl (αR,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-59-1 ethyl 5-(4-<1,1'-biphenyl>yl)-4-<<(1,1-dimethylethoxy)carbonyl>amino>-2-methyl-2-pentenoate 
• 149709-60-4 ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 
• 1426129-50-1 N-[(1R)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 
• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 149709-59-1 (R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid ethyl ester 

Relevant articles and documents

Preparation method of sacubitril intermediate

The invention relates to the technical field of synthesis of medical intermediates, in particular to a preparation method of a sacubitril intermediate, which comprises the following steps: 1) reacting a raw material compound III with phosphorus trihalide to obtain a compound II; and 2) reacting the compound II with phenylhydrazine in the presence of a catalyst and an additive to obtain a sacubitril intermediate, namely a compound I. According to the invention, cheap phosphorus trihalide is selected to replace expensive and highly toxic trifluoromethanesulfonic anhydride, and cheap phenylhydrazine and a catalyst palladium chloride are adopted. The method has the advantages of simple reaction operation, low cost and high yield, and is easier for industrial production of the compound I.

Method for synthesizing AHU377 calcium salt

The invention discloses a method for synthesizing an AHU377 calcium salt. The method comprises the following steps: reacting 4-bromo-D-phenylalanine with thionyl chloride, reacting obtained methyl 4-bromo-D-phenylalaninate hydrochloride with BOC acid anhydride, reacting the obtained reaction product with phenylmagnesium bromide to obtain N-tert-butyloxycarbonyl-amino-4,4-biphenyl-R-alanine methylester, reacting the N-tert-butyloxycarbonyl-amino-4,4-biphenyl-R-alanine methyl ester with sodium borohydride, reacting the obtained reaction product with ethyl 2-(triphenylphosphoranylidene)propionate to obtain ethyl (4R)-5-[1,1'-biphenyl]-4-yl-4-[[tert-butoxycarbonyl]amino]-2-methyl-2-pentenoate, reacting the ethyl (4R)-5-[1,1'-biphenyl]-4-yl-4-[[tert-butoxycarbonyl]amino]-2-methyl-2-pentenoatewith lithium hydroxide, performing catalytic hydrogenation, reacting the obtained catalytic hydrogenation product with thionyl chloride to obtain ethyl (2R, 4S)-5- ([1,1-biphenyl)-4-amino-2-methylpentenoate hydrochloride, and stirring and reacting the ethyl (2R, 4S)-5- ([1,1-biphenyl)-4-amino-2-methylpentenoate hydrochloride, calcium chloride and succinic anhydride to obtain the target product.The method has the advantages of simple steps, mild reaction conditions, high purity and high yield.

Synthesis method of LCZ696 midbody

The invention discloses a synthesis method of an LCZ696 midbody (R)-tertiary butyl (1-([1,1'-biphenyl]-4-base)-3-hydroxyl propane-2-base) carbamic acid ester. The preparation method comprises the following steps that (1) a raw material BOC-D-tyrosine I reacts with substituent sulfonyl chloride to obtain a midbody II; (2) the midbody II and a phenyl Grignard reagent are subjected to coupling to obtain a midbody III; and (3) the midbody III is reduced through potassium borohydride to obtain (R)-tertiary butyl (1-([1,1'-biphenyl]-4-base)-3-hydroxyl propane-2-base) carbamic acid ester IV. The synthesis method utilizes cheap n-tosyl-l-alanyloxyindole to replace expensive and virulent trifluoromethanesulfonic acid, and meanwhile avoids to use the expensive metal catalyst Pd, the experiment is easy to operate, the yield is high, and the LCZ696 midbody is suitable for large-scale production.

NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES

The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone.

R - biphenyl c serinol preparation method (by machine translation)

The invention relates to a preparation method for the intermediate sha kubi tune, in particular to a R - biphenyl c serinol preparation method, steps are as follows: first of all in order to D - tyrosine derivatives as raw materials with different substituted base sulfonic acid chloride (or anhydride) reaction, a compound represented by formula III, the compounds of the formula III are prepared through two routes the third ammonia is mellow R - biphenyl. Route a: type III of a compound represented by formula II shown in the reduction of the compound, then obtained by coupling the third ammonia is mellow R - biphenyl; line II: type III as shown in the coupling shown in formula V compound, further reduction to obtain R - biphenyl the third ammonia is mellow. Prepared by the method of the aforesaid compound R - biphenyl c sphingosine is model antihypertensive medicine LCZ696 (Entresto) of pegvisomant Sacubitril (AHU - 377) key intermediate. The method is simple in operation, short route, is suitable for industrial production. (by machine translation)

PROCESS FOR PREPARATION OF N-BOC BIPHENYL ALANINOL

A process is provided for preparation of (R)-N-Boc biphenyl alaninol.It provides a preparation process for a compound outlined as compound 4, which includes these operations: in one of the alcohol solvents, asymmetric hydrogenation of 5 in the presence of [Rh(Duanphos)(X)]Y and hydrogen to provide compound 4. Here Duanphos is (Rc,Sp)-Duanphos or (Sc,Rp)-Duanphos; X is NBD or/and COD; Y is one or more of BF4, PF6, SbF6. This process has a lot of advantages, such as low cost, safe operation, less pollution and high yield. The product was obtained in >99% purity and ee which is suitable to scale up in industrial scale.

Preparation method of LCZ696 intermediate

The invention discloses a preparation method of LCZ696 intermediate and relates to the technical field of preparation of an aromatic nucleus compound containing 2 benzene rings and 1 chiral center. The preparation method includes the steps of S1, allowing benzyl magnesium bromide to react with methyl oxalyl chloride to obtain a compound as shown in formula I; S2, allowing the compound as shown in formula I to have a bromination reaction with a bromination reagent to generate a compound as shown in formula II; S3, coupling the compound as shown in formula II with phenylboronic acid to obtain a compound as shown in formula III; S4, performing reductive ammoniation on the compound as shown in formula III to obtain a compound as shown in formula IV; S5, applying Boc to the compound as shown in formula IV to obtain a compound as shown in formula V; S6, performing ester group reduction on the compound as shown in formula V to obtain a compound as shown in formula VI. The preparation method has the advantages that overall raw material consumption is lowered, and product productivity and market competiveness are increased; by the overall process optimization, the reaction of each step can be performed and controlled easily, the use of heavy metal catalysts is reduced and avoided, and accordingly the quality index of the final product is increased, and an economic and environment-friendly process route is developed.

Method for preparing Sacubitril intermediate of anti-heart-failure medicine

The invention discloses a method for preparing a Sacubitril intermediate of anti-heart-failure medicine as indicated in the formula (VII).The method comprises the following steps of taking D-phenylalanine which is low in price and easy to obtain as the raw material, and conducting an iodination reaction, an esterification reaction, a Boc protection reaction, a negishi coupling reaction, a DIBAL-H reduction reaction and a wittig reaction, so that the Sacubitril intermediate is obtained through preparation.The method for preparing the Sacubitril intermediate is mild in reaction condition and environmentally friendly, compared with existing preparation methods, the yield is higher, and the method is economical, effective and suitable for large-scale industrialized production.

NOVEL PRODRUGS AND COMBINATIONS FOR TREATMENT OF HYPERTENSION AND CARDIOVASCULAR DISEASES

The invention relates a pharmaceutical composition comprising (i) prodrugs of NEP inhibitors, (ii) mutual prodrugs of angiotensin receptor antagonist and a NEP inhibitor, (iii) a combination of an angiotensin receptor antagonist prodrug and a NEP inhibitor and (iv) a combination of angiotensin receptor antagonist including prodrug, a NEP inhibitor prodrug and a diuretic drug (v) a combination of angiotensin receptor antagonist, a NEP inhibitor prodrug and a calcium channel blocker. The angiotensin receptor antagonist is selected from the group selected from the group consisting of allisartan, elisartan, candesartan, eprosartan, irbesartan, losartan, saprisartan, tasosartan, telmisartan and valsartan. The invention also includes a method for treating hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.

Discovery of pyrrolopyrimidine inhibitors of Akt

The discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts.